^
    4d
    Epithelioid leiomyosarcoma harboring HMGA2::RAD51B fusion: expanding the spectrum of RAD51B-rearranged uterine sarcoma. (PubMed, Virchows Arch)
    The patient remains disease-free at 4 months. This case expands the molecular spectrum of ELMS and, concomitantly, broadens the emerging morphologic spectrum of RAD51B-rearranged uterine sarcomas, underscoring the diagnostic value of fusion testing in unusual uterine mesenchymal neoplasms.
    Journal
    |
    ER (Estrogen receptor) • RAD51B (RAD51 Paralog B) • HMGA2 (High mobility group AT-hook 2)
    |
    Archer® FusionPlex® Sarcoma kit • FusionPlex® Dx
    5d
    PROSARC-1: Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=110, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    PROSARC-2: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. (clinicaltrials.gov)
    P2, N=40, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    Carboplatin monotherapy in recurrent uterine leiomyosarcoma with homozygous BRCA2 deletion: a case report. (PubMed, Int Cancer Conf J)
    Although PARP inhibitors have been utilized in BRCA-mutated ULMS, this case underscores the potential efficacy of platinum-based chemotherapy as an alternative treatment strategy. Furthermore, a therapeutic approach integrating platinum-based chemotherapy followed by PARP inhibitor maintenance, similar to that employed in platinum-sensitive ovarian cancer, warrants further investigation.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    carboplatin
    8d
    A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | N=12 --> 18
    Enrollment change
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    gemcitabine • Fyarro (nanoparticle albumin-bound rapamycin)
    11d
    POTENTIATE: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications (clinicaltrials.gov)
    P1, N=85, Active, not recruiting, Boundless Bio | Recruiting --> Active, not recruiting | N=127 --> 85
    Enrollment closed • Enrollment change • First-in-human
    |
    erlotinib • Lytgobi (futibatinib)
    12d
    A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. (PubMed, Asia Pac J Clin Oncol)
    We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.
    Journal
    |
    CRP (C-reactive protein)
    |
    Halaven (eribulin mesylate)
    12d
    Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Imlygic (talimogene laherparepvec)
    13d
    Real-World Implementation of Next-Generation Sequencing in Sarcoma: Molecular Insights and Therapeutic Outcomes. (PubMed, Med Sci (Basel))
    Genomics-guided therapy in sarcoma is feasible and impactful. Expanding timely access to molecular profiling is essential for advancing precision oncology in the MENA region.
    Retrospective data • Journal • Real-world evidence • Next-generation sequencing • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    TP53 mutation • CDKN2A deletion • RB1 mutation
    14d
    Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study. (PubMed, Nat Commun)
    A phase II is currently exploring this combination in leiomyosarcoma and malignant peripheral nerve sheath tumors. Trial registration: NCT04595994.
    P1 data • Journal
    |
    XPO1 (Exportin 1)
    |
    gemcitabine • Xpovio (selinexor)
    15d
    Primary Renal Fibrosarcoma with Massive Tumor Size and Inferior Vena Cava Extension Mimicking Renal Cell Carcinoma: A Rare Case Report. (PubMed, J Kidney Cancer VHL)
    Despite aggressive pathology, no metastases were identified, and the patient remained recurrence-free at 6 months postoperatively, with chemotherapy reserved for recurrence or metastasis. This report emphasizes the diagnostic challenges, surgical complexity, and clinical significance of primary renal fibrosarcoma and highlights the importance of including it in the differential diagnosis of large renal masses with vascular involvement.
    Journal
    |
    VIM (Vimentin)
    17d
    A Resected Case of Leiomyosarcoma of the Transverse Mesocolon with Difficult Preoperative Diagnosis (PubMed, Gan To Kagaku Ryoho)
    Based on these findings, the tumor was diagnosed as a primary leiomyosarcoma of the transverse mesocolon. The patient has been followed postoperatively without adjuvant therapy, and no signs of recurrence have been observed during the 10 months since surgery.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)